2024
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Mustafa S, Jansen C, Jani Y, Evans S, Zhuang T, Brown J, Nazha B, Master V, Bilen M. The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers. Biomarker Insights 2024, 19: 11772719241254179. PMID: 38827239, PMCID: PMC11143877, DOI: 10.1177/11772719241254179.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune checkpoint inhibitorsResponse to immunotherapyAdverse eventsTreatment of genitourinary malignanciesImmune checkpoint blockadeSelection of therapySignificant side effectsCheckpoint blockadeCheckpoint inhibitorsGU malignanciesGenitourinary malignanciesPatient tumorsTreatment landscapeReview of biomarkersGenitourinary cancersGU tumorsPreclinical studiesPrognostic toolSide effectsTherapyBiomarker developmentTumorPatientsImmunotherapy
2023
Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
Myers A, Briganti A, Leibovich B, Lerner S, Moschini M, Rouprêt M, Shariat S, Spiess P, Stenzl A, Taneja S, Touijer K, Kamat A. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? European Urology Oncology 2023, 7: 412-420. PMID: 37980250, DOI: 10.1016/j.euo.2023.10.028.Peer-Reviewed Original ResearchLymph node dissectionNode dissectionPatient selectionGenitourinary cancersCurrent evidencePathologic nodal stageJudicious patient selectionAdjuvant treatmentNodal stageCollaborative reviewGenitourinary malignanciesTestis cancerTherapeutic benefitDissectionCancerLymphadenectomyLymphHighlight knowledge gapsReference standardContemporary evidenceOngoing areaCumulative benefitsEvidenceSurgeryPenile
2022
Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies.
Zengin Z, Meza L, Malhotra J, Salgia S, Ely J, Hsu J, Kelley E, Mead H, Dizman N, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal S. Waning efficacy of COVID-19 vaccination at six months in patients (pts) with genitourinary malignancies. Journal Of Clinical Oncology 2022, 40: 185-185. DOI: 10.1200/jco.2022.40.6_suppl.185.Peer-Reviewed Original ResearchCOVID-19 vaccinationBlood samplesSystemic treatmentAntibody titersGenitourinary malignanciesSubset of ptsImmune checkpoint inhibitorsBaseline blood samplesLong-term efficacyAdditional blood samplesCOVID-19 vaccineSARS-CoV-2Short-term effectivenessCancer ptsSerologic outcomeCheckpoint inhibitorsGenitourinary cancersMedian ageTherapy cyclesBladder cancerTCR sequencingIgG ELISACoV-2Host immunityVaccination
2021
Abstract PO-041: An immunologic niche of antigen presenting cells and stem-like CD8+ T-cells is present in non-small cell lung cancer brain metastases
Jansen C, del Balzo L, Prabhu R, Logan S, Chappa P, Patel K, Wilkinson S, Lake R, Shu H, Zhong J, Dhere V, Olson J, Sowalsky A, Khan M, Kissick H, Buchwald Z. Abstract PO-041: An immunologic niche of antigen presenting cells and stem-like CD8+ T-cells is present in non-small cell lung cancer brain metastases. Clinical Cancer Research 2021, 27: po-041-po-041. DOI: 10.1158/1557-3265.radsci21-po-041.Peer-Reviewed Original ResearchCD8+ T cellsStem-like CD8+ T cellsNon-small cell lung cancer brain metastasisNon-small cell lung cancerAntigen presenting cellsLung cancer brain metastasisStereotactic radiosurgeryBrain metastasesCancer brain metastasesImmune nicheT cellsPresenting cellsMHC-II+TCF-1CD8+ T cell infiltrationImmunological nichePost-operative stereotactic radiosurgeryPre-operative stereotactic radiosurgeryT cell infiltrationCell lung cancerCohort of patientsCheckpoint blockadePD-1Disease recurrenceGenitourinary malignanciesTesticular Cancer Radiotherapy
Mahal A, Yu J. Testicular Cancer Radiotherapy. Practical Guides In Radiation Oncology 2021, 255-299. DOI: 10.1007/978-3-030-65137-4_12.Peer-Reviewed Original ResearchNonseminoma germ cell tumorsLymph node contouringExcellent survival outcomesGerm cell tumorsSequelae of radiotherapyTreatment planning considerationsDose reduction strategiesPrognostic indicators of relapseIndicator of relapseFollow-up protocolModern radiotherapyRadiotherapy managementRadiotherapy fieldGenitourinary malignanciesCell tumorsSurvival outcomesPrognostic indicatorReview epidemiologyTesticular cancerRadiation treatmentRadiotherapyNational guidelinesBony landmarksAnatomical fieldTreatmentTrends in the use of administrative databases in urologic oncology: 2000 – 2019.
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 – 2019. Journal Of Clinical Oncology 2021, 39: 356-356. DOI: 10.1200/jco.2021.39.6_suppl.356.Peer-Reviewed Original ResearchNational Surgical Quality Improvement ProgramPremier Healthcare DatabaseNational Cancer DatabaseNationwide Inpatient SampleAdministrative databasesUrologic oncologySEER-MedicareSurgical Quality Improvement ProgramStudy periodEnd Results (SEER) databaseQuality Improvement ProgramRepresentative study populationComparative effectiveness researchResults databaseGenitourinary malignanciesInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeTrends in the use of administrative databases in urologic oncology: 2000–2019
Leopold Z, Dave P, Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000–2019. Urologic Oncology Seminars And Original Investigations 2021, 39: 487-492. PMID: 33551250, DOI: 10.1016/j.urolonc.2021.01.014.Peer-Reviewed Original ResearchConceptsAdministrative databasesUrologic oncologyNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramPremier Healthcare DatabaseEnd Results (SEER) databaseNational Cancer DatabaseNationwide Inpatient SampleQuality Improvement ProgramRepresentative study populationComparative effectiveness researchGenitourinary malignanciesResults databaseSEER-MedicareInpatient SampleBladder cancerCancer DatabaseProstate cancerInclusion criteriaStudy populationTreatment trendsAD useHealthcare databasesLarger sample sizeStudy period
2020
The human microbiome and genitourinary malignancies
Nicolaro M, Portal D, Shinder B, Patel H, Singer E. The human microbiome and genitourinary malignancies. Annals Of Translational Medicine 2020, 8: 1245. PMID: 33178777, PMCID: PMC7607065, DOI: 10.21037/atm-20-2976.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsImmune checkpoint inhibitorsTyrosine kinase inhibitorsGenitourinary malignanciesResponse to certain drugsCheckpoint inhibitorsPredictors of diseaseOncological outcomesEffects of antibioticsProstate cancerMicrobial signaturesUrological malignanciesEtiology of disease statesTreatment coursePrognostic indicatorBladder cancerSystemic inflammationHealthy patientsUrinary microbiomeKidney cancerKinase inhibitorsMalignancyGenitourinary diseasesHuman microbiomeTherapeutic targetCancerInequity in selective referral to high-volume hospitals for genitourinary malignancies
Berg S, Tully K, Sahraoui A, Tan W, Krimphove M, Marchese M, Lipsitz S, Noldus J, Trinh Q. Inequity in selective referral to high-volume hospitals for genitourinary malignancies. Urologic Oncology Seminars And Original Investigations 2020, 38: 582-589. PMID: 32217041, DOI: 10.1016/j.urolonc.2020.02.013.Peer-Reviewed Original ResearchConceptsHigh-volume hospitalsBladder cancerPredictors of treatmentCancer patientsRadical prostatectomyProstate cancerMuscle-invasive urothelial bladder cancerNegative predictors of treatmentBlack raceNational Cancer DatabaseNonmetastatic prostate cancerUrothelial bladder cancerProstate cancer patientsBladder cancer patientsMultivariate logistic regression modelAssociated with lower ratesKidney cancer patientsPrivate insurance statusAssociated with lower oddsAssociated with greater oddsLow-volume hospitalsRadical cystectomyReceipt of treatmentGenitourinary malignanciesPerioperative morbidity
2019
Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Abello A, Kenney P. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2019, 411-435. DOI: 10.1007/978-3-030-24378-4_24.Peer-Reviewed Original ResearchRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaDisease-free survivalHigh-risk subsetVenous tumor thrombusTyrosine kinase inhibitorsAdjuvant settingCytoreductive nephrectomyUnresectable diseaseAdjuvant therapyAdvanced diseaseNeoadjuvant therapyOverall survivalTumor thrombusGenitourinary malignanciesPartial nephrectomySignificant causeTherapyEffective agentNephrectomyMonoclonal antibodiesKinase inhibitorsDiseaseAssociations of rurality and disease outcomes in urologic malignancies.
Abello A, Casilla-Lennon M, Kenney P, Leapman M. Associations of rurality and disease outcomes in urologic malignancies. Journal Of Clinical Oncology 2019, 37: 661-661. DOI: 10.1200/jco.2019.37.7_suppl.661.Peer-Reviewed Original ResearchCancer-specific deathAssociation of ruralityUrologic malignanciesKidney cancerPoor cancer-specific survivalCox proportional hazards modelRural statusRural countiesCancer-specific survivalEnd Results (SEER) databaseProportional hazards modelPopulation-level dataDefinitive treatmentRural patientsGenitourinary malignanciesTestis cancerUrologic cancersWorse outcomesCancer incidenceDisease PDisease outcomeUrological cancersMultivariable regressionWhite raceOutcome data
2018
Role of the androgen signaling axis in genitourinary malignancies.
Shinder B, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research 2018, 7: 1135-1142. PMID: 30701159, PMCID: PMC6349041, DOI: 10.21037/tcr.2018.03.41.Peer-Reviewed Original ResearchRenal cell carcinomaGenitourinary malignanciesAndrogen receptorBladder cancerRole of ARAdvanced disease stateProstate cancer developmentNovel therapeutic strategiesCell carcinomaTherapeutic armamentariumTherapeutic strategiesMortality rateCancer developmentMalignancyAndrogensDisease statesCancerCarcinomaProstateArmamentariumMolecular biologyDiseaseProgressionRoleReceptorsReal World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy
Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch A, Oh W, Galsky M, Ahmad J, Odin J. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. Journal Of Clinical Gastroenterology And Hepatology 2018, 2 PMID: 30637414, PMCID: PMC6327955, DOI: 10.21767/2575-7733.1000047.Peer-Reviewed Original ResearchLiver testsCumulative incidenceLiver injuryRenal cell carcinomaReal-world studyElevated LTChemotherapy initiationGenitourinary malignanciesRetrospective reviewCell carcinomaChemotherapeutic agentsAffected patientsChemotherapyClinical significanceClinical trialsTreatment planningPatientsCancer treatmentUndergoing ChemotherapySignificance of drugsULNLT resultsDILITreatmentLiver
2017
Minimally Invasive Therapy for Upper Tract Urothelial Cell Cancer
Pan S, Smith AD, Motamedinia P. Minimally Invasive Therapy for Upper Tract Urothelial Cell Cancer. Journal Of Endourology 2017, 31: 238-245. PMID: 28117602, DOI: 10.1089/end.2016.0475.Peer-Reviewed Original Research
2013
MC13-0070 Whole blood RNA signature as prognostic and predictive biomarker in genitourinary malignancies
Oh W, Venkata U, Wang L, Reese E, Yee T, Kochukoshy T, Tsao C, Galsky M, Zhu J, Gong Y. MC13-0070 Whole blood RNA signature as prognostic and predictive biomarker in genitourinary malignancies. European Journal Of Cancer 2013, 49: s32. DOI: 10.1016/s0959-8049(13)70178-3.Peer-Reviewed Original ResearchUnified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney P, Wood C. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2013, 155-177. DOI: 10.1007/978-1-4614-7236-0_10.Peer-Reviewed Original ResearchSystemic therapyBenefit of cytoreductionTargeted therapy eraVenous tumor thrombusRenal cell carcinomaTyrosine kinase inhibitorsAdjuvant settingUnresectable diseaseAdvanced diseaseCytoreductive surgeryNeoadjuvant therapyTherapy eraAdjuvant therapyMetastatic RCCTumor thrombusGenitourinary malignanciesCell carcinomaPartial nephrectomySurgeryTherapyEffective agentMonoclonal antibodiesKinase inhibitorsDiseaseCurrent role
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply